A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses

Detalles Bibliográficos
Autores principales: Kallen, Karl-Josef, Gnad-Vogt, Ulrike, Scheel, Birgit, Rippin, Gerd, Stenzl, Arnulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991276/
http://dx.doi.org/10.1186/2051-1426-1-S1-P219

Ejemplares similares

Ejemplares similares